<SEC-DOCUMENT>0001140361-23-009098.txt : 20230228
<SEC-HEADER>0001140361-23-009098.hdr.sgml : 20230228
<ACCEPTANCE-DATETIME>20230228112709
ACCESSION NUMBER:		0001140361-23-009098
CONFORMED SUBMISSION TYPE:	DFAN14A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20230228
DATE AS OF CHANGE:		20230228

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMARIN CORP PLC\UK
		CENTRAL INDEX KEY:			0000897448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DFAN14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21392
		FILM NUMBER:		23680834

	BUSINESS ADDRESS:	
		STREET 1:		SPACES SOUTH DOCKLANDS, BLOCK C
		STREET 2:		77 SIR JOHN ROGERSON'S QUAY
		CITY:			DUBLIN 2
		STATE:			L2
		ZIP:			D02 VK60
		BUSINESS PHONE:		353 1 6699 020

	MAIL ADDRESS:	
		STREET 1:		SPACES SOUTH DOCKLANDS, BLOCK C
		STREET 2:		77 SIR JOHN ROGERSON'S QUAY
		CITY:			DUBLIN 2
		STATE:			L2
		ZIP:			D02 VK60

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMARIN PHARMACEUTICALS PLC
		DATE OF NAME CHANGE:	20000201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ETHICAL HOLDINGS PLC
		DATE OF NAME CHANGE:	19930322

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sarissa Capital Management LP
		CENTRAL INDEX KEY:			0001577524
		IRS NUMBER:				900924432
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DFAN14A

	BUSINESS ADDRESS:	
		STREET 1:		660 STEAMBOAT ROAD
		CITY:			GREENWICH
		STATE:			CT
		ZIP:			06830
		BUSINESS PHONE:		203-302-2330

	MAIL ADDRESS:	
		STREET 1:		660 STEAMBOAT ROAD
		CITY:			GREENWICH
		STATE:			CT
		ZIP:			06830
</SEC-HEADER>
<DOCUMENT>
<TYPE>DFAN14A
<SEQUENCE>1
<FILENAME>brhc10048980_dfan14a.htm
<DESCRIPTION>DFAN14A
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 23.1.2.5118
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="text-align: center; font-size: 14pt; font-weight: bold;">UNITED STATES</div>
      <div style="text-align: center; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="text-align: center; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>
      <br>
      <div style="text-align: center; font-size: 18pt; font-weight: bold;">SCHEDULE 14A</div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;">Proxy Statement Pursuant to Section 14(a) of the</div>
      <div style="text-align: center; font-weight: bold;">Securities Exchange Act of 1934</div>
      <br>
      <div>Filed by the Registrant&#8194;&#8201;&#8201;&#9744;</div>
      <br>
      <div>Filed by a party other than the Registrant&#8194;&#8201;&#8201;&#9746;</div>
      <br>
      <div>Check the appropriate box:</div>
      <table cellspacing="0" cellpadding="0" id="zdb95dd674b15472d98dd9b9a01805ab1" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 27pt; vertical-align: top;">&#9744;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Preliminary Proxy Statement</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z1a5209e03be04186812abd4baa0e912d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 27pt; vertical-align: top;">&#9744;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zd469838d212b4e259dad91cb848c8ffd" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 27pt; vertical-align: top;">&#9744;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Definitive Proxy Statement</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zdf539f1b6256479b80bc51565b688737" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 27pt; vertical-align: top;">&#9746;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Definitive Additional Materials</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z4c5a8faf64ea477e8dc19719bba98ad9" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 27pt; vertical-align: top;">&#9744;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Soliciting Material under &#167; 240.14a-12</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: center; font-size: 24pt; font-weight: bold;">Amarin Corporation plc<br>
      </div>
      <div style="text-align: center;">
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;"></div>
      <div style="text-align: center;">
        <div>(Name of Registrant as Specified In Its Charter)</div>
      </div>
      <div style="text-align: center; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; font-weight: bold;">Sarissa Capital Catapult Fund LLC</div>
      <div style="text-align: center; font-weight: bold;">Sarissa Capital Hawkeye Fund LP</div>
      <div style="text-align: center; font-weight: bold;">ISP Fund LP</div>
      <div style="text-align: center; font-weight: bold;">Sarissa Capital Offshore Master Fund LP</div>
      <div style="text-align: center; font-weight: bold;">Sarissa Capital Master Fund II LP</div>
      <div style="text-align: center; font-weight: bold;">Sarissa Capital Athena Fund Ltd</div>
      <div style="text-align: center; font-weight: bold;">Atom Master Fund LP</div>
      <div style="text-align: center; font-weight: bold;">Sarissa Capital Fund GP LP</div>
      <div style="text-align: center; font-weight: bold;">Sarissa Capital Fund GP LLC</div>
      <div style="text-align: center; font-weight: bold;">Sarissa Capital Offshore Fund GP LLC</div>
      <div style="text-align: center; font-weight: bold;">Sarissa Capital Management GP LLC</div>
      <div style="text-align: center; font-weight: bold;">Sarissa Capital Management LP</div>
      <div style="text-align: center; font-weight: bold;">Alexander J. Denner, Ph.D.</div>
      <div style="text-align: center; font-weight: bold;">Patrice Bonfiglio</div>
      <div style="text-align: center; font-weight: bold;">Paul Cohen, M.D.</div>
      <div style="text-align: center; font-weight: bold;">Mark DiPaolo</div>
      <div style="text-align: center; font-weight: bold;">Keith L. Horn</div>
      <div style="text-align: center; font-weight: bold;">Odysseas Kostas, M.D.</div>
      <div style="text-align: center; font-weight: bold;">Louis Sterling III</div>
      <div style="text-align: center; font-weight: bold;">Diane E. Sullivan</div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      <div style="padding-top: 1pt;">
        <div style="text-align: center;">&#160;(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</div>
        <br>
      </div>
      <div>Payment of Filing Fee (Check all boxes that apply):</div>
      <table cellspacing="0" cellpadding="0" id="z8ce7e1fcbf844b988b10bbab7215115d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 27pt; vertical-align: top;">&#9746;</td>
            <td style="width: auto; vertical-align: top;">
              <div>No fee required</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z030f16eb237a499f9596478b8b4f44bf" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 27pt; vertical-align: top;">&#9744;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Fee paid previously with preliminary materials</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z10258b538d6940529a985a84a304957a" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 27pt; vertical-align: top;">&#9744;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11</div>
            </td>
          </tr>

      </table>
      <br>
      <div>
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div>This filing contains a press release issued on February 28, 2023 by Sarissa Capital.</div>
      <br>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="font-style: italic;">
        <div style="text-align: center; font-weight: bold; font-style: normal;">SARISSA CAPITAL WINS PROXY CONTEST AGAINST AMARIN BY HUGE LANDSLIDE</div>
        <div style="font-style: normal;"><br>
        </div>
        <div style="text-align: center; font-weight: bold; font-style: normal;">Sarissa honored to have received 100 million more votes than Amarin board</div>
        <div style="font-style: normal;"><br>
        </div>
        <div style="text-align: justify; font-style: normal;">Greenwich, CT, February 28, 2023 &#8211; Sarissa Capital Management LP today issued the following statement regarding Amarin Corporation plc (NASDAQ: AMRN):</div>
        <div style="font-style: normal;"><br>
        </div>
        <div style="font-style: normal;">Amarin shareholders have sent a loud and clear message repudiating the incumbent Amarin board. Sarissa thanks fellow shareholders for their support in a resounding victory against the Amarin board. Our estimate is
          that up to nearly 80% of shareholder votes were in support of Sarissa. As Amarin&#8217;s largest shareholder, we are grateful for the opportunity to remake Amarin for the benefit of all shareholders.</div>
        <div style="font-style: normal;"><br>
        </div>
        <div style="font-style: normal;">Vascepa, the foundation on which Amarin is built, is a tremendous drug that is compelling for patients and payors &#8211; a unique proposition for a drug. While there is a lot of work to be done, we remain confident in
          our ability to leverage Vascepa&#8217;s rare and highly beneficial profile to unlock tremendous value for all shareholders.</div>
        <div style="font-style: normal;"><br>
        </div>
        <div style="font-weight: bold; font-style: normal;"><u>LET&#8217;S GET TO WORK AND FINALLY BEGIN RUNNING AMARIN FOR THE BENEFIT OF ALL SHAREHOLDERS!</u></div>
        <div style="font-style: normal;"><br>
        </div>
        <div style="font-weight: bold; font-style: normal;">Additional Information</div>
        <div style="font-style: normal;"><br>
        </div>
        <div style="font-style: normal;">Sarissa Capital Management LP (&#8220;Sarissa Capital&#8221;), together with other participants, filed a definitive proxy statement and an accompanying blue proxy card with the SEC on January 31, 2023, in connection with the
          solicitation of shareholders of Amarin Corporation plc (the &#8220;Company&#8221;) at the general meeting of the Company for the election of Sarissa Capital&#8217;s slate of highly-qualified nominees (the &#8220;General Meeting&#8221;). Shareholders are advised to read the
          definitive proxy statement and other relevant documents related to the General Meeting as they contain important information.</div>
        <div style="font-style: normal;"><br>
        </div>
        <div style="font-style: normal;">The definitive proxy statement and other relevant documents are available at no charge on the SEC&#8217;s website at <u>www.sec.gov</u> and at <u>www.freeamarin.com</u>. The definitive proxy statement and other relevant
          documents are also available at no charge by directing a request to Sarissa Capital&#8217;s proxy solicitor, D.F. King &amp; Co., Inc., 48 Wall Street, New York, New York 10005 (Shareholders can call toll-free: (800) 331-7024).</div>
        <div style="font-style: normal;"><br>
        </div>
        <div style="font-style: normal;">#FreeAmarin </div>
        <div style="font-style: normal;"><br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6bc51860e70e44d1a9aa0cdb4c18bf0d">

            <tr>
              <td style="width: 72pt; vertical-align: top; font-style: normal;">Contact:</td>
              <td style="width: auto; vertical-align: top; font-style: normal;">
                <div>Dayna Packes<br>
                  Sarissa Capital Management LP<br>
                  info@sarissacap.com</div>
              </td>
            </tr>

        </table>
        <div style="font-style: normal;"><br>
        </div>
      </div>
      <div> <br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
